SCHEMBL5953217

SCHEMBL5953217

CC(=O)OCC#CC[NH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487316 0.87 ALDH1A1 (0.50)
SCHEMBL15177595 0.78 ALDH1A1 (0.42)
SCHEMBL576725 0.78
SCHEMBL1969901 0.78
SCHEMBL8167088 0.76
SCHEMBL5208163 0.76
SCHEMBL1969198 0.76
SCHEMBL965654 0.76
SCHEMBL5952894 0.76 ALDH1A1 (0.40)
SCHEMBL577216 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100269-A1 Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders LAMBROU GEORGE N 2006-05-11 US disclosed
EP-1589963-A1 USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS Novartis AG (CH) 2005-11-02 EP disclosed
WO-2004066993-A1 USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS NOVARTIS AG (CH) 2004-08-12 WO disclosed
WO-2003057204-A2 MODULATION OF IAMT (PIMT OR PCMT) IN IMMUNE SYSTEM NORDIC BIOSCIENCE A/S (DK) 2003-07-17 WO disclosed
US-5780501-A ADMINISTERING TO A MAMMAL NOVARTIS CORPORATION (US) 1998-07-14 US disclosed
US-5780500-A Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi b,f! oxepines NOVARTIS CORPORATION (US) 1998-07-14 US disclosed